Elaine Wangsawidjaja
Associate
Australia and New Zealand, Securities and Capital Markets
Sydney
+61 2 4003 3626
Elaine advises clients on a wide range of US law transactional matters. In particular, Elaine focuses on private placements, entitlement offers, NASDAQ listings and SEC filings by Australian companies.
Selected Experience
- Bionomics/Neuphoria on its re-domiciliation from Australia to Delaware with listing on Nasdaq
- Mesoblast on A$260 million placement with resale registration statement on Form F-3
- Goodman Group on A$4 billion placement
- Xero on A$1.85 billion placement
- Vulcan Energy on A$1 billion accelerated non renounceable entitlement offer and placement
- Ryman Healthcare on NZ$1 billion entitlement offer and placement
- AUB on A$400 million placement
- Spartan Resources on A$220 million placement
- Clarity Pharmaceuticals on A$203 million placement
- Austal on A$200 million placement
- Capricorn Metals on A$200 million placement
- EBOS on A$200 million placement
- Catalyst Metals on A$150 million placement
- Chimeric Develop Global on A$180 million placement
- betr Entertainment on A$130 million entitlement offer and placement
- IperionX on A$100 million placement
- WA1 Resources on A$100 million placement
- Virgin Australia on IPO
- Saluda Medical, Inc. on IPO
- BMC Minerals Ltd. on IPO
News, Events, & Insights
- Neuphoria Therapeutics Ring the Nasdaq Opening Bell
News March 6, 2025
- Rimon advises Aussie biotech on re-domiciliation and listing on Nasdaq as a Delaware company
News January 23, 2025


